Peptinovo Biopharma
Nanotechnology platform delivering chemotherapy drugs selectively to cancer cells, enhancing treatment efficacy and safety.
| Date | Investors | Amount | Round |
|---|---|---|---|
* | $1.4m Valuation: $20.4m | Series A | |
| Total Funding | 000k | ||
Related Content
Peptinovo Biopharma, Incorporated is a biotechnology company focused on revolutionizing cancer treatment through its innovative drug delivery platform. The company operates in the biopharmaceutical market, primarily targeting oncology. Peptinovo's core product is its nanotechnology platform, which allows leading chemotherapy drugs to be selectively delivered to cancer cells. This approach aims to improve the efficacy of cancer treatments while minimizing harmful side effects such as nerve damage, hair loss, and nausea, which are commonly associated with traditional chemotherapy.
Peptinovo's primary clients include healthcare providers, oncology specialists, and pharmaceutical companies seeking advanced solutions for cancer treatment. The company generates revenue through partnerships, licensing agreements, and the sale of its proprietary drug delivery technology. By enhancing the safety and effectiveness of established chemotherapies, Peptinovo aims to improve patient outcomes and quality of life.
The business model is centered around the development and commercialization of its drug delivery platform, with a focus on reducing dose-limiting side effects and improving patient safety. Peptinovo's flagship product, PNB 281, is designed to mitigate peripheral neuropathy caused by paclitaxel, a widely used chemotherapy drug. This technology has the potential to be applied to various types of cancer, offering a broad market opportunity.
Keywords: nanotechnology, drug delivery, chemotherapy, cancer treatment, oncology, biopharmaceutical, peripheral neuropathy, patient safety, PNB 281, paclitaxel.